Fig. 6. Antitumor effects of Annexin A5-AH5 fusion protein.

BALB/c mice were injected with 5 × 10⁵ CT-26 cells/mouse subcutaneously on day 0. Mice were then treated intraperitoneally with 5 mg/kg cisplatin on days 10 and 13 and intravenously with 200jig/mice of AnxA5, 200jig/mice of AnxA5-AH5, and/or 3.5jig/mice of AH5 peptide on days 11, 12, 14, and 15. The treatment groups are as follows: cross—PBS only; opened square—AH5 peptide only; opened sphere—Annexin A5 only; opened triangle—Annexin A5 and AH5 peptide; opened circle—Annexin A5-AH5 only; star mark—cisplatin only; closed square—cisplatin and AH5 peptide; closed sphere—cisplatin and Annexin A5; closed circle—cisplatin and Annexin 5A-AH5; closed triangle—cisplatin, Annexin A5, and AH5 peptide. a Schematic diagram. b Line graph depicts CT-26 tumor growth in different treatment groups over time (n = 10). P-values were determined by one-way ANOVA and Turkey’s test. c Kaplan–Meier survival analysis of CT-26 tumor-bearing mice in different treatment groups (n = 10), and the overall P-value was calculated by the log-rank test. d–e On days 16 and 21, tumor tissues and spleens of CT26 tumor-bearing mice in different treatment groups were harvested and analyzed for CD8+IFN-γ+ T cells by flow cytometry analysis, respectively. d Representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+ T cells in splenocytes of CT-26 tumor bearing mice in different treatment groups (n = 3). e Representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+tumor-infiltrating T cells in CT-26 tumor bearing mice in different treatment groups (n = 3). The error bars indicate mean ± SD. For (d, e), P-values were analyzed by Student’s t test. The results are representative of one of three independent experiments. Source data are provided as a Source Data file.